Implementation of molecular phenotyping approaches in the personalized surgical patient journey

Annals of Surgery

Volumn 255, Issue 5, 2012, Pages 881-889

  Mirnezami, Reza ^a   Kinross, James M ^a   Vorkas, Panagiotis A ^b   Goldin, Robert ^a   Holmes, Elaine ^b   Nicholson, Jeremy ^b   Darzi, Ara ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Faculty of Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

BREAST CANCER; CANCER GROWTH; CANCER RESEARCH; COLORECTAL CANCER; DATA ANALYSIS; HUMAN; INTENSIVE CARE; LUNG CANCER; METABOLIC PROFILING TECHNOLOGY; METABONOMICS; MOLECULAR GENETICS; PERIOPERATIVE PERIOD; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEPSIS; SURGICAL INJURY; SURGICAL PATIENT; TISSUE SECTION;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENERAL SURGERY; HUMANS; INDIVIDUALIZED MEDICINE; LEAST-SQUARES ANALYSIS; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NEOPLASMS; PERIOPERATIVE PERIOD; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRESS, PHYSIOLOGICAL; WOUNDS AND INJURIES;

EID: 84859920644     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31823e3c43     Document Type: Review

References (88)

1. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology.Mol Syst Biol. 2006;2:52.
2. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134:714-717.
3. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
4. Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011;57:231-240.
5. Ritchie SA, AhiahonuPW, Jayasinghe D, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010;8:13.
6. Wang W, Feng B, Li X, et al. Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst. 2010;6:1947-1955.
7. Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.
8. Carrola J, Rocha CM, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 2011;10:221-230.
9. Garcia E, Andrews C, Hua J, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res. 2011;10:1765-1771.
10. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolutionmagic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009;8:352-361.
11. Chen JL, Tang HQ, Hu JD, et al. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry.World JGastroenterol. 2010;16:5874-5880.
12. Rocha CM, Barros AS, Gil AM, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010;9:319-332.
13. Jordan KW, Nordenstam J, Lauwers GY, et al. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum. 2009;52:520-525.
14. Sitter B, Bathen TF, Singstad TE, et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010;23:424-431.
15. Thysell E, Surowiec I, Hornberg E, et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One. 2010;5:e14175.
16. Ludwig C, Viant MR. Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem Anal. 2010;21:22-32.
17. Cooks RG, Busch KL, Glish GL. Mass spectrometry: analytical capabilities and potentials. Science. 1983;222:273-291.
18. Nambiar PR, Gupta RR, Misra V. An "Omics" based survey of human colon cancer. Mutat Res. 2010;693:3-18.
19. Urayama S, et al. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom. 2010;24:613-620.
20. Vinayavekhin N, Saghatelian A. Untargeted metabolomics. Curr Protoc Mol Biol. 2010;Chapter 30:Unit 30.1.1-24.
21. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 2007;387:525-527. (Pubitemid 46067468)
22. Daffertshofer A, Lamoth CJ, Meijer OG, et al. PCA in studying coordination and variability: a tutorial. Clin Biomech (Bristol, Avon). 2004;19:415-428. (Pubitemid 38510420)
23. Boulesteix AL, Strimmer K. Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform. 2007;8:32-44. (Pubitemid 46157928)
24. Smith CA, Want EJ, O'Maille G, et al. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78:779-787. (Pubitemid 43228585)
25. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37(Database issue):D603-D610.
26. Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35(Database issue):D521-D526. (Pubitemid 46056263)
27. Sana TR, Roark JC, Li X, et al. Molecular formula and METLIN Personal Metabolite Database matching applied to the identification of compounds generated by LC/TOF-MS. J Biomol Tech. 2008;19:258-266.
28. Smith CA, O'Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27:747-751. (Pubitemid 44391729)
29. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
30. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr Relat Cancer. 2010;17:R287-R304.
31. Annibaldi A,Widmann C. Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care. 2010;13:466-470.
32. Sattler UG, Hirschhaeuser F, Mueller-Klieser WF. Manipulation of glycolysis in malignant tumors: fantasy or therapy? Curr Med Chem. 2010;17: 96-108.
33. Ong ES, Zou L, Li S, et al. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis [published online ahead of print February 10, 2010].Mol Cell Proteomics. DOI:10.1074/mcp.M900551-MCP200
34. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30:377-386.
35. O'Byrne KJ, Dalgleish AG, Browning MJ, et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000;36:151-169. (Pubitemid 30102191)
36. Yakoub D, Keun HC, Goldin R, et al. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res. 2010;70:9129-9136.
37. Lampidis TJ, Kurtoglu M, Maher JC, et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol. 2006;58:725-734. (Pubitemid 44351251)
38. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2004;53: 116-122. (Pubitemid 38186989)
39. Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31-34. (Pubitemid 38114078)
40. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65:613-621.
41. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-4646. (Pubitemid 44187614)
42. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria as targets for chemotherapy. Apoptosis. 2009;14:624-640.
43. Denkert C, Budczies J,Weichert W, et al.Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008;7:72.
44. Qiu Y, Cai G, Su M, et al. Urinary metabonomic study on colorectal cancer. J Proteome Res. 2010;9:1627-1634.
45. Oakman C, Tenori L, Claudino WM, et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol. 2011;22:1295-1301.
46. Weljie AM, Jirik FR.Hypoxia-induced metabolic shifts in cancer cells:Moving beyond the Warburg effect. Int J Biochem Cell Biol. 2011;43:981-989.
47. Bathen TF, Jensen LR, Sitter B, et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2007;104:181-189. (Pubitemid 47086272)
48. Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010;70:8309-8318.
49. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-914.
50. Maxeiner A, Adkins CB, Zhang Y, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate. 2010;70:710-717.
51. Beckonert O, Coen M, Keun HC, et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc. 2010;5:1019-1032.
52. Schwamborn K, Caprioli RM. MALDI imaging mass spectrometry-painting molecular pictures. Mol Oncol. 2010;4:529-538.
53. Layfield DM, Agrawal A, Roche H, et al. Intraoperative assessment of sentinel lymph nodes in breast cancer. Br J Surg. 2011;98:4-17.
54. Ashford RU, Scolyer RA, McCarthy SW, et al. The role of intra-operative pathological evaluation in the management of musculoskeletal tumours. Recent Results Cancer Res. 2009;179:11-24.
55. Tempfer CB, Polterauer S, Bentz EK, et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol. 2007;107:248-252. (Pubitemid 47575720)
56. Haun JB, Castro CM,Wang R, et al.Micro-NMR for RapidMolecularAnalysis of Human Tumor Samples. Sci Transl Med. 2011;3:71.
57. McDonnell LA, Corthals GL, Willems SM, et al. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics. 2010;73:1921-1944.
58. ElAyed M, BonnelD, Longuespee R, et al.MALDI imagingmass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit. 2010;16:BR233-BR245.
59. Lemaire R, Menguellet SA, Stauber J, et al. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res. 2007;6:4127-4134. (Pubitemid 350158491)
60. Patel SA, Barnes A, Loftus N, et al. Imaging mass spectrometry using chemical inkjet printing reveals differential protein expression in human oral squamous cell carcinoma. Analyst. 2009;134:301-307.
61. Shimma S, Sugiura Y, Hayasaka T, et al. MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;855:98-103. (Pubitemid 47077722)
62. Bouslimani A, Bec N, Glueckmann M, et al. Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney. Rapid Commun Mass Spectrom. 2010;24:415-421.
63. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32:1928-1948. (Pubitemid 39202372)
64. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008; Crit Care Med. 2008;36:296-327.
65. Moore LJ, Moore FA, Jones SL, et al. Sepsis in general surgery: a deadly complication. Am J Surg. 2009;198:868-874.
66. Galley HF. Bench-to-bedside review: targeting antioxidants to mitochondria in sepsis. Crit Care. 2010;14:230.
67. Russell JA.Gene expression in human sepsis:what havewe learned? Crit Care. 2011;15:121.
68. Ait-Oufella H, Maury E, Lehoux S, et al. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med. 2010;36:1286-1298.
69. LosserMR, Damoisel C, PayenD. Bench-to-bedside review: glucose and stress conditions in the intensive care unit. Crit Care. 2010;14:231.
70. Lin ZY, Xu PB, Yan SK, et al. A metabonomic approach to early prognostic evaluation of experimental sepsis by 1H NMR and pattern recognition. NMR Biomed. 2009;22:601-608.
71. Stringer KA, Serkova NJ, Karnovsky A, et al. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol. 2011;300:L4-L11.
72. Mao H, Wang H, Wang B, et al. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J Proteome Res. 2009;8:5423-5430.
73. Hortal J, Munoz P, Cuerpo G, et al. Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe. Crit Care. 2009;13:R80.
74. Stephan R, Cernela N, Ziegler D, et al. Rapid species specific identification and subtyping of Yersinia enterocolitica by MALDI-TOF Mass spectrometry. J Microbiol Methods. 2011;87:150-153.
75. Backman C, Taylor G, Sales A, et al. An integrative review of infection prevention and control programs for multidrug-resistant organisms in acute care hospitals: a socio-ecological perspective. Am J Infect Control. 2011;39:368-378.
76. Slupsky CM, Cheypesh A, Chao DV, et al. Streptococcus pneumoniae and Staphylococcus aureus pneumonia induce distinct metabolic responses. J Proteome Res. 2009;8:3029-3036.
77. Osipov GA, Verkhovtseva NV. Study of human microecology by mass spectrometry of microbial markers. Benef Microbes. 2011;2:63-78.
78. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol. 2011;14:82-91.
79. Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics. 2011;12:103-111.
80. Shamir MY, Kaplan L, Marans RS, et al. Urine flow is a novel hemodynamic monitoring tool for the detection of hypovolemia. Anesth Analg. 2011;112:593-596.
81. Seear MD, Scarfe JC, LeBlanc JG. Predicting major adverse events after cardiac surgery in children. Pediatr Crit Care Med. 2008;9:606-611.
82. Kapoor PM, Kakani M, Chowdhury U, et al. Early goal-directed therapy in moderate to high-risk cardiac surgery patients. Ann Card Anaesth. 2008;11:27-34.
83. Ingelmo P, Barone M, Fumagalli R. Importance of monitoring in high risk surgical patients. Minerva Anestesiol. 2002;68:226-230. (Pubitemid 41750851)
84. Kinross JM, Alkhamesi N, Barton RH, et al. Global metabolic phenotyping in an experimental laparotomy model of surgical trauma. J Proteome Res. 2011;10:277-287.
85. Rosner MH. Urinary biomarkers for the detection of renal injury. Adv Clin Chem. 2009;49:73-97.
86. Schafer KC, Szaniszlo T, Gunther S, et al. In situ, real-time identification of biological tissues by ultraviolet and infrared laser desorption ionization mass spectrometry. Anal Chem. 2011;83:1632-1640.
87. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBS J. 2007;274:1140-1151.
88. Backshall A, Sharma R, Clarke SJ, et al. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res. 2011;17:3019-3028.